Open AccessPCSK9 inhibition to reduce cardiovascular disease risk
Author(s) -
Hagai Tavori,
Ilaria Giunzioni,
Sergio Fazio
Publication year - 2015
Publication title -
current opinion in endocrinology, diabetes and obesity./current opinion in endocrinology, diabetes and obesity
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.199
H-Index - 67
eISSN - 1752-2978
pISSN - 1752-296X
DOI - 10.1097/med.0000000000000137
Subject(s) - pcsk9 , proprotein convertase , kexin , ldl receptor , lipoprotein , postprandial , cholesterol , bioinformatics , low density lipoprotein , statin , disease , medicine , pharmacology , biology , endocrinology , diabetes mellitus
Review novel insights into the biology of proprotein convertase subtilisin/kexin 9 (PCSK9) that may explain the extreme efficiency of PCSK9 inhibition and the unexpected metabolic effects resulting from PCSK9 monoclonal antibody therapy, and may identify additional patients as target of therapy.